Business
Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across ADC Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer at WCLC
TOKYO & BASKING RIDGE, N.J., August 14, 2025--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25).
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":226,"height":223,"url":"https://media.zenfs.com/en/business-wire.com/70fa5039c5d0517919a69cac03866041"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/q.32e7MmqwvutYLAZe8aBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/70fa5039c5d0517919a69cac03866041","width":226,"height":223}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Late-breaking data from IDeate-Lung01 phase 2 trial demonstrate potential of ifinatamab deruxtecan to become first-in-class B7-H3 directed ADC for pretreated extensive-stage small cell lung cancer","length":196,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Investor briefing to discuss WCLC data and ifinatamab deruxtecan clinical development program","length":93,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., August 14, 2025--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio in lung cancer at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25).","length":328,"tagName":"p"},{"type":"text","content":"Data at WCLC will showcase the company’s progress towards creating new standards of care for patients with lung cancer, including a late-breaking oral presentation featuring the primary analysis from the dose optimization and dose expansion parts of the IDeate-Lung01 phase 2 trial (OA06.03) of ifinatamab deruxtecan (I-DXd) in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC). Interim data from the dose optimization part of the trial was previously presented at 2024 WCLC.","length":499,"tagName":"p"},{"type":"text","content":""The late-breaking data at WCLC continues to demonstrate the potential of ifinatamab deruxtecan to become a first-in-class B7-H3 directed antibody drug conjugate for patients with pretreated extensive-stage small cell lung cancer, where treatment options following platinum-based chemotherapies are limited," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "The...